tbuckley/cabot-search huggingface dataset:
SARS-CoV-2 infection is associated with an increased risk of idiopathic acute pancreatitis but not pancreatic exocrine insufficiency or diabetes: long-term results of the COVIDPAN study
Authors: Manu Nayar, Chris Varghese, Aditya Kanwar, Ajith K Siriwardena, Ali Raza Haque, Altaf Awan, Anita Balakrishnan, Arab Rawashdeh, Bogdan Ivanov, Chetan Parmar, Christopher M Halloran, Clifford Caruana, Cynthia-Michelle Borg, Dhanny Gomez, Dimitrios Damaskos, Dimitrios Karavias, Guy Finch, Husam Ebied, James K Pine, James R A Skipworth, James Milburn, Javed Latif, Jeyakumar Apollos, Jihène El Kafsi, John A Windsor, Keith Roberts, Kelvin Wang, Krish Ravi, Maria V Coats, Marianne Hollyman, Mary Phillips, Michael Okocha, Michael SJ Wilson, Nadeem A Ameer, Nagappan Kumar, Nehal Shah, Pierfrancesco Lapolla, Connor Magee, Bilal Al-Sarireh, Raimundas Lunevicius, Rami Benhmida, Rishi Singhal, Srinivasan Balachandra, Semra Demirli Atıcı, Shameen Jaunoo, Simon Dwerryhouse, Tamsin Boyce, Vasileios Charalampakis, Venkat Kanakala, Zaigham Abbas, Nilanjana Tewari, Sanjay Pandanaboyana
Journal: Gut (2021)

We recently published in GUT the outcomes of acute pancreatitis (AP) and coexisting SARS-CoV-2 infection.1 A number of patients who were SARS-CoV-2 positive had AP of unknown aetiology (25%) speculating SARS-CoV-2 as a cause for AP similar to other viruses.2 However, most patients did not complete investigations to exclude other causes of AP. In addition, SARS-CoV-2 infection may cause aberrant glycometabolic control,3 however it is unknown if this increases the risk of long-term diabetes mellitus (DM). The follow-up data were collected 12 months from the date of recruitment for 1476 patients (118 patients who were SARS-CoV-2 positive and 1358 patients who were negative) to establish an aetiology for AP and development of DM. Among the 118 patients who were SARS-CoV-2 positive, 35 patients had idiopathic or unknown aetiology AP. Sixteen patients underwent either MRCP (n=13) or EUS (n=4) and the remaining patients underwent biochemical investigations to exclude other causes of AP. The final aetiology of AP was available for 83 (70.3%) patients and included gallstones (56, 47.4%), alcohol (19, 16.1%), post ERCP (2, 1.7%) and other (6, 5.1%). Overall, 23 patients had a change of aetiology, and in 35 (29.7%) patients AP was considered idiopathic. Patients who were SARS-CoV-2 positive were more likely to have idiopathic AP (34.7% vs 13.9%, p<0.001) with over five times increased risk after adjusting for age, smoking status, body mass index and ethnicity (OR: 5.34, p<0.001) (table 1 and online supplemental table S1).### Supplementary data

[gutjnl-2021-326218supp002.pdf]

View this table:

Table 1 
Comparison of baseline characteristics of all patients in the follow-up cohort by aetiology



Thirteen (11.0%) patients in the SARS-CoV-2 positive group and 187 (13.8%) patients in the negative group were readmitted with AP (p=0.949). The aetiology and baseline characteristics are summarised in online supplemental table S2. The risk of readmission was higher in younger …
Bcl2 Inhibitor and DNA Hypomethylating Agent Prolong Survival in Patient-Derived Xenograft Model of Down Syndrome Myeloid Leukemia By Synergistic Downregulation of Cytokine Signaling
Authors: Sonali P. Barwe, Erin Lynn Crowgey, Qinzhuo Zhang, E. Anders Kolb, Anilkumar Gopalakrishnapillai
Journal: Blood (2021)
Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment
Authors: Oliver Van Oekelen, Sarita Agte, Adolfo Aleman, Bhaskar Upadhyaya, Charles R. Gleason, Komal Srivastava, Katherine F. Beach, Kevin Tuballes, Katerina Kappes, Tarek H. Mouhieddine, Bo Wang, Seunghee Kim-Schulze, Ajai Chari, Sacha Gnjatic, Nina Bhardwaj, Brian D. Brown, Miriam Merad, Carlos Cordon-Cardo, Florian Krammer, Sundar Jagannath, Viviana Simon, Ania Wajnberg, Samir Parekh
Journal: Blood (2021)
sEVsRVG selectively delivers antiviral siRNA to fetus brain, inhibits ZIKV infection and mitigates ZIKV-induced microcephaly in mouse model
Authors: Rui Zhang, Yuxuan Fu, Min Cheng, Wenyuan Ma, Nan Zheng, Yongxiang Wang, Zhiwei Wu
Journal: Molecular Therapy (2021)

Zika virus (ZIKV), a flavivirus associated with neurological disorders, constitutes a global health threat. During pregnancy, ZIKV traverses the placenta and causes congenital disease such as microcephaly and Guillain-Barré syndrome in newborns. To develop a specific antiviral therapy against ZIKV-induced microcephaly that could cross placental and blood-brain barriers, we designed targeted small extracellular vesicles (sEVs) encapsulating antiviral siRNA (small interfering RNA) to inhibit ZIKV. The neuro-specific targeting was achieved by engineering EVs membrane protein lamp2b fused with a neuron-specific rabies virus glycoprotein derived peptide (RVG). Intravenous administration of the RVG-engineered sEVs loaded with siRNA (ZIKV-specific siRNA) protected pregnant AG6 mice against vertical transmission of ZIKV. Particularly, sEVsRVG-siRNA traversed placental and blood-brain barriers and suppressed ZIKV infection in fetal brains. Moreover, sEVsRVG-siRNA alleviated the neuroinflammation and neurological damage caused by ZIKV in the fetal mouse model. In general, we developed a sEVs-based targeted system of antiviral therapy for brain and fetal brain infections. Zika virus (ZIKV), a flavivirus associated with neurological disorders, constitutes a global health threat. During pregnancy, ZIKV traverses the placenta and causes congenital disease such as microcephaly and Guillain-Barré syndrome in newborns. To develop a specific antiviral therapy against ZIKV-induced microcephaly that could cross placental and blood-brain barriers, we designed targeted small extracellular vesicles (sEVs) encapsulating antiviral siRNA (small interfering RNA) to inhibit ZIKV. The neuro-specific targeting was achieved by engineering EVs membrane protein lamp2b fused with a neuron-specific rabies virus glycoprotein derived peptide (RVG). Intravenous administration of the RVG-engineered sEVs loaded with siRNA (ZIKV-specific siRNA) protected pregnant AG6 mice against vertical transmission of ZIKV. Particularly, sEVsRVG-siRNA traversed placental and blood-brain barriers and suppressed ZIKV infection in fetal brains. Moreover, sEVsRVG-siRNA alleviated the neuroinflammation and neurological damage caused by ZIKV in the fetal mouse model. In general, we developed a sEVs-based targeted system of antiviral therapy for brain and fetal brain infections.
Change in Patients' Perceived Cognition Among Chimeric Antigen Receptor T-Cell Therapy Recipients at Day 360
Authors: Anna Barata, Aasha I. Hoogland, Anuhya Kommalapati, Jennifer M Logue, Kelly A. Hyland, Sarah L. Eisel, Brent J. Small, Taylor Welniak, Nathaly Irizarry-Arroyo, Yvelise Rodriguez, Reena Jayani, Margaret Booth-Jones, Laura B. Oswald, Brian D. Gonzalez, Kedar Kirtane, Michael D. Jain, Sepideh Mokhtari, Julio C. Chavez, Aleksandr Lazaryan, Bijal D. Shah, Frederick L. Locke, Heather S. L. Jim
Journal: Blood (2021)
Abstract 8918: Nstemi in a Patient With Anomalous Coronary Artery Origin
Authors: priscilla A ababio, Hilda M Gonzalez Bonilla, Ahmad A Awan, isaac opoku-asare
Journal: Circulation (2021)

Introduction: Anomalous origin of the coronary arteries is a rare condition that can be life threatening. We present the case of a patient with anomalous right coronary artery (RCA) origin who presented with atypical chest pain. Case Presentation: A 34-year old man with no medical history presented with atypical chest pain. Initial vital signs were within normal limits and physical examination was unremarkable. Laboratory results revealed a peak troponin of 16.56 Ng/ml and EKG did not show ischemic changes. Echocardiogram demonstrated mildly impaired right ventricular systolic function. Cardiac catheterization showed patent coronaries and anomalous RCA arising from the left coronary cusp (LCC). Cardiac CT showed anomalous origin of the RCA extending from the LCC and coursing between the aorta and the pulmonary artery. Patient remained asymptomatic and was referred for surgical evaluation Discussion: Anomalous RCA originating from the LCC occurs in 0.05%-0.1% of the general population. It may run posterior to the aorta, anterior to the pulmonary trunk, septal or between the pulmonary artery and the aorta itself, like in the case of our patient. Diagnosis of these anomalies can be done by cardiac MRI, cardiac coronary CT, or coronary angiography. Management depends on the nature of the anomalies and remains controversial. Options include coronary angioplasty, conservative medical management, or surgical correction. In patients with intramural course and symptoms of myocardial ischemia, most literature recommends surgical intervention. Conclusions: This case illustrates a unique case of a patient with an anomalous coronary artery origin presenting with NSTEMI. Management can be challenging, and it must be individualized.
Abstract 13829: Association Between E-wave Propagation Index and Left Ventricular Thrombus Formation in Systolic Heart Failure
Authors: Caroline L Bjerregaard, Morten Sengelov, Peter G Jorgensen, Niels Bruun, Thomas Fritz-Hansen, Rajat Mittal, Tor Biering-Sørensen, Flemming J Olsen
Journal: Circulation (2021)

Background: The E-wave propagation index (EPI) is a measure of apical blood flow and has been proposed as a risk marker of left ventricular thrombus (LVT) formation. We sought to investigate the association between EPI and LVT in patients with heart failure with reduced ejection fraction (HFrEF). Methods: This was a retrospective cohort study of patients with HFrEF. Follow-up echocardiograms were investigated for development of LVT. EPI was measured at baseline investigation as the velocity time integral of the transmitral E-wave divided by the left ventricular length. Logistic regression was used to investigate the association between EPI and LVT. Multivariable adjustments were made for age, significant mitral regurgitation, apical aneurysm, prior myocardial infarction, and left ventricular ejection fraction (LVEF). Results: Of 785 patients, 24 (3%) developed LVT. Mean age was 66 years, 73% were men, and LVEF was 28%. Those who developed LVT had significantly lower EPI (1.12 vs. 1.36, p=0.02). EPI was significantly associated with LVT in univariable logistic regression (OR=1.16 (1.03-1.31), per 0.1 decrease) (figure). These findings were unchanged after multivariable adjustments (OR=1.15 (1.00-1.31), per 0.1 decrease). The EPI provided an area under the curve of 0.68 with an optimal cutoff of 1.2. This cutoff had a sensitivity of 75%, specificity of 60%, positive predictive value of 6%, and negative predictive value of 99%. A low EPI was associated with a more than 4-fold increased risk of LVT (OR=4.56 (1.79-11.62), p=0.001). Conclusion: Decreasing EPI is associated with a higher risk of LVT. While a low EPI poses a markedly increased risk of LVT, a high EPI may be used to rule out LVT.
Abstract 9147: Reduced Delta-6-Desaturase Activity May Be Associated With Major Adverse Cardiac Events During 2 Years Follow Up in Elderly Patients With a Recent Myocardial Infarction
Authors: Dennis W Nilsen, Peder L Myhre, Are Annesoenn Kalstad, Erik Berg Schmidt, Harald Arnesen, Ingebjorg Seljeflot
Journal: Circulation (2021)

Background: Low levels of dihomo-gamma linolenic acid (DGLA) have been related to a bad outcome in patients with acute coronary syndromes. Reduced levels of DGLA may result from reduced conversion of its precursor linoleic acid (LA). An increase in the ratio of LA to DGLA (LA:DGLA) has been shown to reflect reduced delta-6-desaturase activity. Aim: To evaluate the association between the LA:DGLA ratio, reflecting delta-desaturase activity, and the risk of major adverse cardiovascular event (MACE, comprising nonfatal myocardial infarction (MI), unscheduled revascularization, stroke, hospitalization for heart failure, or all-cause death), in patients with a recent MI. Methods: Baseline samples from the OMEMI (Omega-3 Fatty acids in Elderly with Myocardial Infarction) trial* in which a total of 1027 patients, age 70 to 82 years, were included 2-8 weeks after an MI and followed up for 2 years, were used. FAs were measured in serum phospholipids, and the LA:DGLA ratio was calculated at baseline and related to incident MACE by univariate and multivariable Cox regression analyses, adjusted for age, sex, body mass index, omega-3 supplementation at baseline and hypertension. Results: A total of 208 patients experienced MACE during follow-up. The univariate hazard ratio (HR) for MACE in the fourth quartile (Q4) of LA:DGLA compared to the lowest quartile (Q1) was 1.49 (95% confidence interval (CI), 1.00-2.23), p=0.005. After adjustment, the HR for Q4 was weakened [1.47 (0.97-2.25), p=0.072]. The HR for Q2-4 combined as compared to Q1 was borderline significant [1.42 (0.99-2.03)], p=0.055. Although the number of total deaths were more than two-fold higher in Q4 as compared to Q1 [HR 2.30 (1.04-5.06), p=0.038], this did not reach significance in the adjusted models [HR 2.26 (0.95-5.37), p=0.065], and remained non-significant when comparing Q2-4 combined to Q1 [HR 1.74 (0.80-3.77), p=0.16]. Conclusion: Higher levels of LA:DGLA ratio were found to be associated with MACE in elderly patients with a recent MI, suggesting a mechanism to why low levels of DGLA may be associated with increased adverse events. * Circulation 2021; 143(6): 528-39.
A Phase 2 Study Evaluating the Addition of Ublituximab and Umbralisib (U2) to Ibrutinib in Patients with Chronic Lymphocytic Leukemia (CLL): A Minimal Residual Disease (MRD)-Driven, Time-Limited Approach
Authors: Lindsey E. Roeker, Lori A. Leslie, Jake D. Soumerai, Victoria Falco, Gail Panton, Andrew D. Zelenetz, Lorenzo Falchi, Jae H Park, Camila Pena-Velasquez, Sonia Lebowitz, Kristen Battiato, Carissa Laudati, Meghan C. Thompson, David J. Straus, Yehudit Fox, Elizabeth McCarthy, Sabrina Kdiry, Rosalba Martignetti, Hari P. Miskin, Peter Sportelli, Anthony R. Mato
Journal: Blood (2021)
The IL-3, IL-5, and GM-CSF common receptor beta chain mediates oncogenic activity of FLT3-ITD-positive AML
Authors: Anne Charlet, Max Kappenstein, Philip Keye, Kathrin Kläsener, Cornelia Endres, Teresa Poggio, Sivahari P. Gorantla, Stefanie Kreutmair, Jana Sänger, Anna L. Illert, Cornelius Miething, Michael Reth, Justus Duyster, Christoph Rummelt, Nikolas von Bubnoff
Journal: Leukemia (2021)

Abstract FLT3-ITD is the most predominant mutation in AML being expressed in about one-third of AML patients and is associated with a poor prognosis. Efforts to better understand FLT3-ITD downstream signaling to possibly improve therapy response are needed. We have previously described FLT3-ITD-dependent phosphorylation of CSF2RB, the common receptor beta chain of IL-3, IL-5, and GM-CSF, and therefore examined its significance for FLT3-ITD-dependent oncogenic signaling and transformation. We discovered that FLT3-ITD directly binds to CSF2RB in AML cell lines and blasts isolated from AML patients. A knockdown of CSF2RB in FLT3-ITD positive AML cell lines as well as in a xenograft model decreased STAT5 phosphorylation, attenuated cell proliferation, and sensitized to FLT3 inhibition. Bone marrow from CSF2RB-deficient mice transfected with FLT3-ITD displayed decreased colony formation capacity and delayed disease onset together with increased survival upon transplantation into lethally irradiated mice. FLT3-ITD-dependent CSF2RB phosphorylation required phosphorylation of the FLT3 juxtamembrane domain at tyrosines 589 or 591, whereas the ITD insertion site and sequence were of no relevance. Our results demonstrate that CSF2RB participates in FLT3-ITD-dependent oncogenic signaling and transformation in vitro and in vivo. Thus, CSF2RB constitutes a rational treatment target in FLT3-ITD-positive AML.
NCOG-04. THE IMPACT OF PROPHYLAXIS CHEMOTHERAPY ON CENTRAL NERVOUS SYSTEM (CNS) RELAPSES OF HIGH RISK DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): A NETWORK META-ANALYSIS
Authors: Philip Haddad, Dalia Hammoud, Kevin Gallagher
Journal: Neuro-Oncology (2021)

Abstract BACKGROUND CNS relapses with DLBCL tend to be uncommon. The risk increases with certain DLBCL types and certain identified risk features. There is no consensus regarding the optimal approach to CNS prophylaxis for high-risk DLBCL patients. While some favor prophylaxis with high-dose systemic therapy or intrathecal chemotherapy (IT), some experts advocate combining both approaches. In the absence of randomized trials, the role of chemotherapy prophylaxis remains controversial in DLBCL with contradictory comparative studies. The purpose of this meta-analysis is to evaluate the impact of CNS prophylaxis approaches on the clinical outcomes of high-risk DLBCL. METHODS A review of the medical literature was conducted using online databases. Inclusion criteria consisted of DLBCL diagnosis, English language, IT or high-dose systemic prophylactic chemotherapy, and comparative studies reporting CNS recurrence rates. A frequentist and Bayesian network meta-analysis were conducted using the netmeta package and random-effects model. RESULTS Twenty-one comparative studies with a total of 11,507 patients were included and analyzed. The relative risk (RR) of CNS recurrence was not statistically different between IT prophylaxis, high-dose chemotherapy, and no prophylaxis. However, the combination of IT prophylaxis and high-dose chemotherapy was found to be significantly associated with a reduced RR of CNS recurrence when compared to IT prophylaxis (RR 0.28, 95%CI 0.13-0.58), high-dose chemotherapy (RR 0.34, 95%CI 0.14-0.80), and no prophylaxis (RR 0.41, 95%CI 0.19-0.87). CONCLUSIONS This network meta-analysis is the first to compare the different CNS prophylactic approaches. It indicates that IT prophylaxis and high-dose chemotherapy each were not better than no prophylaxis. However, the combination of IT prophylaxis with high-dose chemotherapy was significantly superior to each approach alone as well as no prophylaxis. In the absence of randomized clinical trials, this network meta-analysis represents the most compelling data supporting the use of CNS prophylaxis in patients with high-risk DLBCL.
Combined +58 and +55 <i>BCL11A</i> enhancer Editing Yields Exceptional Efficiency, Specificity and HbF Induction in Human and NHP Preclinical Models
Authors: Jing Zeng, Selami Demirci, My Anh Nguyen, Linda Yingqi Lin, Stacy A. Maitland, Esther Mintzer, Yuxuan Wu, Danilo Pellin, Amornrat Tangprasittipap, Chokdee Vong, Shaina N. Porter, Kevin Luk, Pengpeng Liu, Varun Katta, Marioara-Felicia Ciuculescu, Daniela Abriss, Jonathan Hsu, Naoya Uchida, Khaled Essawi, Robert Donahue, Karl Petri, Vikram Pattanayak, Luca Pinello, Christian Brendel, David A Williams, John P Manis, Shengdar Q. Tsai, Shondra M. Pruett-Miller, J. Keith Joung, Duantida Songdej, Suradej Hongeng, Myriam Armant, Scot A. Wolfe, John F. Tisdale, Daniel E. Bauer
Journal: Blood (2021)
Biosimulation Using the Cellworks Computational Omics Biology Model (CBM) Identifies Immune Modulation As a Key Pathway for Predicting Azacitidine (AZA) Response in Myelodysplastic Syndromes (MDS)
Authors: Scott C Howard, Ansu Kumar, Michael Castro, Himanshu Grover, Subrat Mohapatra, Shweta Kapoor, Anuj Tyagi, Prashant Ramachandran Nair, Rakhi Purushothaman Suseela, Anusha Pampana, Deepak Anil Lala, Divya Singh, Vijayashree P Shyamasundar, Shruthi Kulkarni, Yugandhara Narvekar, Kritika Sahni, Rahul K Raman, Veena Balakrishnan, Mamatha Patil, Naga Ganesh Palaniyeppa, Ashokraja Balla, Sanjana Patel, Nirjhar Mundkur, James Christie, Michele Dundas Macpherson, Guido Marcucci
Journal: Blood (2021)
Impact of Tet2 Deficiency, and of <i>TET2</i> Mutations in Clonal Hematopoiesis, on Neutrophil/Granulocyte Immune Function
Authors: Elina K Cook, Michael Luo, Jeffrey Mewburn, Kimberly J Dunham-Snary, Charles Hindmarch, Stephen L Archer, Michael J Rauh
Journal: Blood (2021)
Very Low-Dose Dasatinib Is a Safe and Effective Therapy for Elderly Patients with Newly-Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results from the Davlec Study, a Single-Arm, Multicenter, Phase 2 Trial
Authors: Takashi Kumagai, Kazunori Murai, Hiroshi Ureshino, Hideo Tanaka, Kaichi Nishiwaki, Satoshi Wakita, Koiti Inokuchi, Toshihiro Fukushima, Chikashi Yoshida, Masayuki Mita, Nobuhiko Uoshima, Toru Kiguchi, Jun Aoki, Satoshi Kimura, Kaori Karimata, Kensuke Usuki, Joji Shimono, Yoshiaki Chinen, Junya Kuroda, Yasufumi Matsuda, Kensuke Nakao, Takaaki Ono, Katsumichi Fujimaki, Hirohiko Shibayama, Chisaki Mizumoto, Tomoharu Takeoka, Katsuhiro Io, Takeshi Kondo, Masatomo Miura, Yosuke Minami, Takayuki Ikezoe, Jun Imagawa, Ayako Takamori, Atsushi Kawaguchi, Junichi Sakamoto, Shinya Kimura
Journal: Blood (2021)
Deep Phenotyping Reveals Expansion of T Follicular Regulatory Cells and Triple Positive (CTLA4, TIGIT, PD1) Exhausted Effector Memory T Cells Characterizing the Immunosuppressive Microenvironment in Follicular Lymphoma
Authors: Sary El Daker, Daniel Freeman, Jeeyeon Baik, Menglei Zhu, Pratip Chattopadhyay, Mikhail Roshal, Ahmet Dogan, Pallavi Galera
Journal: Blood (2021)
Severe High Molecular Weight Kininogen (HK) Deficiency: Clinical Characteristics, Deficiency-Causing KNG1 Variants in Reported and New Cases, and Estimated Prevalence
Authors: Anke Adenaeuer, Stefano Barco, Alice Trinchero, Hanan Nazir, Sarah Krutmann, Chiara Ambaglio, Vincenzo Rocco, Ylenia Pancione, Luigi Tomao, Arlette Ruiz de Saez, Marion Echenagucia, Friederike Häuser, Karl J. Lackner, Heidi Rossmann, Bernhard Lämmle
Journal: Blood (2021)
Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist
Authors: Gerulf Hänel, Anne-Sophie Neumann, Vesna Pulko, Christina Claus, Alexandra Leutbecher, Anetta Marcinek, Nora Zieger, Veit L Buecklein, Pablo Umana, Christian Klein, Marion Subklewe
Journal: Blood (2021)
Mgta-145 + Plerixafor Provides GCSF-Free Rapid and Reliable Hematopoietic Stem Cell Mobilization for Autologous Stem Cell Transplant in Patients with Multiple Myeloma: A Phase 2 Study
Authors: Surbhi Sidana, Andriyana K Bankova, Hitomi Hosoya, Shaji Kumar, John Tamaresis, Anne Le, Lori Muffly, Laura J. Johnston, Sally Arai, Robert Lowsky, Everett H Meyer, Andrew R. Rezvani, Wen-Kai Weng, Matthew J. Frank, Parveen Shiraz, Douglas Girgenti, Kevin A. Goncalves, Veit Schmelmer, John C. Davis, Ying Lu, Judith A Shizuru, David B. Miklos
Journal: Blood (2021)
Epidermal Growth Factor-like 7 As a Novel Therapeutic Target in Mantle Cell Lymphoma
Authors: Chinmayee Goda, Sofia Kolovich, Rohan SUDHIR Kulkarni, Malith Karunasiri, Alex Ruddich, Eric Nauman, Satishkumar Singh, Girish Rajgolikar, Ramiro Garzon, Lalit Sehgal, Adrienne M. Dorrance
Journal: Blood (2021)